Microbiota-derived butyrate inhibits cDC development via HDAC inhibition, diminishing their ability to prime T cells

Anna Andrusaite, Jennifer Lewis, Annika Frede, Andrew Farthing, Verena Kästele, Jennifer Montgomery, Allan Mowat, Elizabeth Mann, Simon Milling*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Conventional dendritic cells (cDC) are central to maintaining the balance between protective immune responses and tolerance to harmless antigens, especially in the intestine. Short chain fatty acids (SCFAs) such as butyrate play critical roles in regulating intestinal immunity, but the underlying mechanisms remain unclear. Here we demonstrate that microbiota-derived butyrate alters intestinal cDC populations in vivo resulting in decreased numbers of the cDC2 lineage. By establishing a novel in vitro culture model, we show that butyrate has a direct and selective ability to repress the development of cDC2 from cDC precursors, an effect that is independent of G-protein coupled receptors (GPCRs) and is due to inhibition of histone deacetylase 3. Finally, cDC derived from pre-cDC in the presence of butyrate in vitro express lower levels of costimulatory molecules and have a decreased ability to prime naïve T cells. Together, our data show that butyrate affects the developmental trajectory of cDC, selectively repressing the cDC2 lineage and reducing their ability to stimulate T cells. These properties may help explain the ability of butyrate to maintain homeostasis in the intestine.
Original languageEnglish
Article number17(6)
Pages (from-to)1199-1211
Number of pages12
JournalMucosal Immunology
Volume17
Issue number6
DOIs
Publication statusPublished - 13 Aug 2024

Fingerprint

Dive into the research topics of 'Microbiota-derived butyrate inhibits cDC development via HDAC inhibition, diminishing their ability to prime T cells'. Together they form a unique fingerprint.

Cite this